

C1q Human

Description: Human Complement Component C1q produced in Human plasma having a molecular mass of 410 kDa.

Synonyms: Component C1q, Complement C1q, Complement Component C1q, C1q.

Source: Human Plasma.

Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.

Purity: Greater than 96.0%.

Formulation:

Lyophilized from 0.01M Na₂ EDTA solution containing 0.3M NaCl pH 7.5.

Stability:

Human C1q although stable at room temperature for 3 weeks, should be stored between 2-8°C.
Do not freeze!

Usage:

NeoBiolab's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Solubility:

It is recommended to reconstitute the lyophilized C1q in sterile 18M-cm H₂O.

Introduction:

C1q is the first component of the classical pathway of complement activation. C1q along with the enzymatically active components C1r and C1s forms the C1 complex. When C1 binds to immunoglobulins in the form of immune complexes, it leads to activation of C1r and C1s proteases and a further activates the classical pathway of complement. C1q is a glycoprotein that belongs to the collectin family, having a molecular weight of about 410-462 kDa. C1q is a hexamer composed of globular heads attached to collagen-like triple-helix tails. The globular heads of C1q exclusively bind to the CH₂ domain of IgG molecules or the CH₃ domain of IgM. Each heavy chain of the immunoglobulin molecule contains a single binding site for C1q. Given that C1q must bind to no less than two heavy chains in order to alter its conformation and activate C1r and C1s, its activation follows only after binding to immunoglobulins in the form of immune complexes bound to multivalent antigens. C1q's main physiological role is in the clearance of immune complexes and apoptotic bodies from the organism. Interruption of this process may lead to development of autoimmunity. Individuals with genetic deficiencies of C1q or other components of the classical pathway are at risk to develop SLE. C1q specifically binds to apoptotic bodies of human keratinocytes, vascular endothelial cells and lymphocytes. Complement components C1q and bound C3 mediate the clearance of apoptotic bodies. Hence, C1q may advance the clearance of autoantigens, avoiding stimulation of the immune system. Nonetheless, an extended exposition of the immune system to the neopeptide exposed on C1q molecules bound to immune complexes or apoptotic bodies could ultimately lead to an autoimmune response against C1q itself and to an altered complement function. C1q deficiency may also lead to disruption of the negative selection of autoreactive B cells. C1q along with other specific recognition proteins bind to the highly conserved lupus antigens (dsDNA and nuclear proteins) and activate the complement system.

www.neobiolab.com

info@neobiolab.com

888.754.5670, +1 617.500.7103 United States

0800.088.5164, +44 020.8123.1558 United Kingdom

Autoantibodies against C1q (anti-C1q) are found in a number of autoimmune and infectious diseases like glomerulonephritis (GN) and lupus erythematosus (SLE), these antibodies are significant in clinical practice due to their negative predictive value.



Catalog #:PRPS-561

To place an order, please [Click HERE](#).

For research use only.

© 2015 NeoScientific



neobiolab | Term | Quote/Order | Services | Products | Support | Corporate | Contact Us

Copyrights @ 2013 NEO Group 245 First Street, 18th Floor, Cambridge MA 02142 888.754.5670 (toll-free)



Request a
CATALOG
[CLICK HERE](#)